Syntara Limited is a clinical-stage biotechnology company specializing in the development of innovative therapies for hematological malignancies and diseases driven by inflammation and fibrosis. The company's core focus is on correcting extracellular matrix (ECM) dysfunction—a key factor in abnormal tissue scarring and immune responses—using its expertise in amine oxidase chemistry. Syntara’s research pipeline is anchored by lead candidates such as SNT-5505, which is currently in Phase 2 clinical trials for myelofibrosis, a blood cancer associated with bone marrow fibrosis. Additional programs are directed at myelodysplastic syndrome, chronic organ fibrosis, and neuroinflammatory disorders, including projects in collaboration with leading research partners. The company’s strategy centers on inhibiting specific oxidase enzymes that regulate fibrosis and inflammation, aiming to address high-unmet medical needs in both rare and chronic conditions. Syntara Limited plays a critical role in Australia’s biotech sector, contributing to medical advancements and emerging as an important player in the global drug development landscape focused on serious, hard-to-treat diseases.